Abstract
This chapter covers the variety of substances listed in Table 8.1, each of which can enhance sensory perceptions such as colors and sounds. However, the hallucinogens rarely produce schizophrenialike auditory hallucinations without insight in the context of a clear sensorium and, thus, are not truly “psychotomimetic.”1–4 In fact, when hallucinations do occur at high doses of these drugs, they are usually visual in nature, most often involving lights, colors, or geometric shapes, and the user is likely to understand (or have insight) into the relationship between the drug and the hallucinations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goodwin, D. W., & Guze, S. B. Psychiatric diagnosis (5th ed.). New York: Oxford University Press, 1996.
O’Brien, C. P. Drug addiction and drug abuse. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, et al. (Eds.), The pharmacological basis of therapeutics (9th ed.). New York: McGraw-Hill, 1995, pp. 557–577.
Crowley, T. J. Hallucinogen-related disorders. In H. I. Kaplan & B. J. Saddock (Eds.), Comprehensive textbook of psychiatry (6th ed.). Baltimore, MD: Williams & Wilkins, 1995, pp. 831–838.
Pechnick, R. N., & Ungerleider, J. T. Hallucinogens. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Lan-grod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 230–238.
Halpern, J. H. The use of hallucinogens in the treatment of addiction. In Addiction research (Vol. 4). Amsterdam: Harwood Academic Publishers, 1996, pp. 177–189.
Krebs-Thomson, R., Paulas, M. P., & Geyer, M. A. Effects of hallucinogens on locomotor and investigatory activity and patterns: Influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 18:339–351, 1998.
Vollenweider, F. X., Vontobel, P., Hell, D., & Leenders, K. L. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man—A PET study with [11C]raclopride. Neuropsychopharmacology 20:424–433, 1999.
Aghajanian, G. K., & Marek, G. J. Serotonin and hallucinogens, Neuropsychopharmacology 21(Suppl): 16S–23S, 1999.
Kramer, H. K., Poblete, J. C., & Azmitia, E. C. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: Evidence for a presynaptic localization involving the serotonin transporter (SERT). Neuropsychopharmacology 19:265–277, 1998.
Morgan, M. J. Recreational use of “ecstasy” (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 19:252–264, 1998.
Winger, G., Hofmann, F. G., & Woods, J. H. A handbook on drug and alcohol abuse (3rd ed.). New York: Oxford University Press, 1992, pp. 98–115.
Strassman, R. J., Quails, C. R., & Berg, L. M. Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-dimethyltryptamine in humans. Biological Psychiatry 39:784–795, 1996.
Schuckit, M. A. Educating yourself about alcohol and drugs. New York: Plenum Publishing Co., 1998.
Grob, C. S., & Poland, R. E. MDMA. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 269–275.
Schuckit, M. A. MDMA (ecstasy): An old drug with new tricks. Vista Hill Foundation Newsletter, 23(2), 1994.
Schlemmer, R. F., Jr., Nawara, C., Heinze, W. J., et al. Influence of environmental context on tolerance to LSD-induced behavior in primates. Biological Psychiatry 21:314–317, 1986.
American Psychiatric Association. The diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Press, 1994.
Brown, J. K., & Malone, M. H. Some U.S. street drug identification programs. Journal of the American Pharmaceutical Association 13:670–674, 1973.
Cohen, R. S. Adverse symptomatology and suicide associated with the use of methylenedioxy-methamphet-amine (MDMA; “Ecstasy”). Biological Psychiatry 39:819–820, 1996.
Curran, H. V., & Travill, R. A. Mood and cognitive effects of ±3,4-methylenedioxymetham phetamine (MDMA, ‘ecstasy’): Week-end ‘high’ followed by mid-week low. Addiction 92:821–831, 1997.
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241–251, 1998.
Peroutka, S. J. (Ed.). Ecstasy: The clinical, pharmacological, and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers, 1990.
Steele, T. D., McCann, U. D., & Ricaurte, G. A. 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): Pharmacology and toxicology in animals and humans. Addiction 89:539–551, 1994.
Kalivas, P. W., Duffy, P., & White, S. R. MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology 18:469–479, 1998.
Green, A. R., Cross, A. J., & Goodwin, G. M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”). Psychopharmacology 119:247–260, 1995.
Krystal, J. H., & Price, L. H. Chronic MDMA use: Effects on mood and neuropsychological function? American Journal of Drug and Alcohol Use 18:331–341, 1992.
Steele, T. D., McCann, U. D., & Ricaurte, G. A. 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Pharmacology and toxicology in animals and humans. Addiction 59:539–551, 1994.
Substance Abuse and Mental Health Services Administration, Office of Applied Studies. National Household Survey on drug abuse: Population estimates 1997. Rockville, MD: U.S. Department of Health and Human Services, 1998.
Johnston, L. D., O’Malley, P. M., & Bachman, J. G. National survey results on drug use from the Monitoring the Future Study, 1975–1997, Vol. I, Secondary School Students. Rockville, MD: National Institute on Drug Abuse, U.S. Department of Health and Human Services, 1998.
Cuomo, M. J., Dyment, P. G., & Gammino, V. M. Increasing use of “ecstasy” (MDMA) and other hallucinogens on a college campus. Journal of American College of Health 42:271–274, 1994.
Schuster, P., Lieb, R., Lamertz, C., & Wittchen, H. U. Is the use of ecstasy and hallucinogens increasing? Results from a community study. European Addiction Research 4:75–82, 1998.
Editorial. Epidemiology of drug usage. Lancet 1:147-148, 1985.
Abruzzi, W. Drug-induced psychosis. International Journal of the Addictions 12:183–193, 1977.
Bondi, M. W., Drake, A. I., & Grant, I. Verbal learning and memory in alcohol abusers and polysubstance abusers with concurrent alcohol abuse. Journal of the International Neuropsychological Society 4:319–328, 1998.
Krystal, J. H., & Price, L. H. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: Effects on mood and neuropsychological function. American Journal of Drug and Alcohol Abuse 18:331–341, 1992.
Kawasaki, A., & Purvin, V. Persistant palinopsia following ingestion of lysergic acid diethylamide (LSD). Archives of Ophthalmology 114:47–50, 1996.
Gouzoulis, E., Borchardt, D., & Hermle, L. A case of toxic psychosis induced by “Eve” (3,4-methylene-dioxymethamphetamine). Archives of General Psychiatry 50:75, 1993.
Hermle, L., Funfgeld, M., Oepen, G., et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biological Psychiatry 32:976–991, 1992.
Goldstein, J. A. Niacin and acute psychedelic psychosis. Biological Psychiatry 19:272–273, 1984.
Ungerleider, J. T., & Pechnick, R. N. Hallucinogens. In J. H. Lowinson, P. Ruiz, R. B. Millman, & J. G. Langrod (Eds.), Substance abuse: A comprehensive textbook (3rd ed.). Baltimore, MD: Williams & Wilkins, 1996, pp. 230–238.
Lerner, A. G., Oyffe, I., Isaacs, G., & Signal, M. Protracted akathisia after risperidone withdrawal. American Journal of Psychiatry 154:437–438, 1997.
Lerner, A. G., Finkel, B., Oyffe, I., et al. Clonidine treatment for hallucinogen persisting perception disorder. American Journal of Psychiatry 155:1460, 1998.
McCann, U. D., & Ricaurte, G. A. MDMA “ecstasy” and panic disorder: Induction by a single dose. Biological Psychiatry 32:950–953, 1992.
Gouzoulis, E., Steiger, A., Ensslin, M., Kovar, A., & Hermle, L. Sleep EEG effects of 3,4-methylene-dioxymethamphetamine (MDE; “Eve”) in healthy volunteers. Biological Psychiatry 32:1108–1117, 1992.
Price, L. H., Ricuarte, G. A., Krystal, J. H., & Heninger, G. R. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Archives of General Psychiatry 46:18–22, 1989.
Smith, C. G., & Asch, R. H. Drug abuse and reproduction. Fertility and Sterility 48:355–373, 1987.
Abraham, H. D., & Aldridge, A. M. Adverse consequences of lysergic acid diethylamide. Addiction 88:1327–1334, 1993.
Redfearn, P. J., Agrawal, N., & Mair, L. H. An association between the regular use of 3,4-methylene-dioxymethamphetamine (Ecstasy) and excessive wear of the teeth. Addiction 93:745–748, 1998.
Kokotos Leonardi, E. T., & Azmitia, E. C. MDMA (Ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231–238, 1994.
Bowen, J. S., Davis, G. B., Kearney, T. E., & Bardin, J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethyoxyamphetamine ingestion. Journal of the American Medical Association 249:1477–1479, 1983.
Schuckit, M. A. The kitchen condiment high: Nutmeg. Vista Hill Foundation Newsletter, 26(6), 1997.
Fink, P. J., Goldman, M. J., & Lyons, I. Morning glory seed psychosis. Archives of General Psychiatry 15:209–213, 1966.
Pfister, J. A., Stegelmeier, B. L., Cheney, C. D., et al. Operant analysis of chronic locoweed intoxication in sheep. Journal of Animal Science 74:2622–2632, 1996.
Schuckit, M. A. Betel nut: A widespread drug of abuse. Vista Hill Foundation Drug Abuse & Alcoholism Newsletter, 21(1), 1992.
Talonu, N. T. Observations on betel nut use, habituation, addiction, and carcinogenesis. Papua New Guinea Medical Journal 32:195–197, 1989.
Zacny, J. P., Cho, A. M., Toledano, A. Y., et al. Effects of information on the reinforcing, subjective, and psychomotor effects of nitrous oxide in healthy volunteers. Drug & Alcohol Dependence 48:85–95, 1997.
Zacny, J. P., Klafta, J. M., Coalson, D. W., et al. The reinforcing effects of brief exposures to nitrous oxide in healthy volunteers. Drug and Alcohol Dependence 42:197–200, 1996.
Matthew, R. J., Wilson, W. H., Humphreys, D., & Lowe, J. V. Effect of nitrous oxide on cerebral blood velocity while reclining and standing. Biological Psychiatry 41:979–984, 1997.
Haverkos, H. W., & Drotman, D. P. NIDA technical review: Nitrate inhalants. Biomedicine & Pharmacotherapy 50:228–230, 1996.
Schuckit, M. A. The nitrite inhalants. Vista Hill Foundation Drug Abuse & Alcoholism Newsletter, 19(10), 1990.
Dax, E. M., Lange, W. R., & Jaffe, J. H. Allergic reactions to amyl nitrite inhalation. American Journal of Medicine 86:732, 1989.
Brandes, J. C., Bufill, J. A., & Pisciotta, A. V. Amyl nitrite-induced hemolytic anemia. American Journal of Medicine 86:252–254, 1989.
Mirvish, S. S., & Haverkos, H. W. Butyl nitrite in the induction of Kaposi’s sarcoma in AIDS. New England Journal of Medicine 317:1603, 1987.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schuckit, M.A. (2000). Hallucinogens and Related Drugs. In: Drug and Alcohol Abuse. Critical Issues in Psychiatry. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3232-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3232-0_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-3234-4
Online ISBN: 978-1-4757-3232-0
eBook Packages: Springer Book Archive